# EDGAR Filing Document

**Accession Number:** 0001701541
**File Stem:** 0001104659-25-117310
**Filing Date:** 2025-12
**Character Count:** 2694
**Document Hash:** 014959ec79022fe446cded48e4c4f757
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-117310.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0001104659-25-117310

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Black Diamond Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001701541
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 245 FIRST STREET, 18TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-417-5868

**MAIL ADDRESS:**
- **STREET 1:** 245 FIRST STREET, 18TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aset Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20170321

**VIA EDGAR** 

December 1, 2025

United States Securities and Exchange Commission

Office of Life Sciences<br> Division of Corporation Finance<br> 100 F Street, N.E.<br> Washington, D.C. 20549

Attention: Jason Drory

---

| | |
|:---|:---|
| **Re:** | **Black Diamond Therapeutics, Inc.<br> Acceleration Request for Registration Statement on Form S-3**<br> **Filed on November 13, 2025** |

---

**File No.** **333-291518**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Black Diamond Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to December 3, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072. If you have any questions regarding this request, please contact Adam V. Johnson.

---

| |
|:---|
| Sincerely, |
| BLACK DIAMOND THERAPEUTICS, INC. |
| /s/ Mark A. Velleca |
| Mark A. Velleca |
| President and Chief Executive Officer |

---

cc: Brent Hatzis-Schoch, Esq., *Black Diamond Therapeutics, Inc.*

Erika Jones, *Black Diamond Therapeutics, Inc.*

Robert E. Puopolo, Esq., *Goodwin Procter LLP*

Adam V. Johnson, Esq., *Goodwin Procter LLP*